Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Pyxis Oncology, Inc.NASDAQ: PYXS
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$466.45M, compared with -$384.71M a year earlier.
Context
- Retained earnings amounted to 725.4% of total assets at the end of Q1 FY2026, up 442.3 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -21.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (443.18M) USD
- Year-over-year change
- -21.9%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (443.18M) | -21.9% |
| FY2024 | 2024-12-31 | (363.56M) | -27.0% |
| FY2023 | 2023-12-31 | (286.23M) | -34.7% |
| FY2022 | 2022-12-31 | (212.44M) | -131.6% |
| FY2021 | 2021-12-31 | (91.72M) | — |
Retained Earnings vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's Mar 2026 retained earnings of -$466.45M is the 3rd highest of the 10 companies compared; the peer median is -$621.6M.
- Its year-over-year change of -21.2% is the 5th highest of 10, against a peer median of -27.3%.
- Retained earnings amounts to 725.4% of total assets for PYXS, versus a peer median of 216.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | -$248.77M | -43.5% | — | 108.8% |
| Mar 2026 | -$429.96M | -16.8% | — | 136.6% | |
| Mar 2026 | -$466.45M | -21.2% | — | 725.4% | |
| Mar 2026 | -$473.84M | -32.7% | — | 216.0% | |
| Mar 2026 | -$568.01M | -42.5% | — | 212.7% | |
| Mar 2026 | -$621.6M | -27.3% | — | 417.2% | |
| Mar 2026 | -$624.28M | -15.3% | — | 462.2% | |
| Mar 2026 | -$652.34M | -13.1% | — | 293.6% | |
| Mar 2026 | -$744.47M | -15.1% | — | 673.4% | |
| Mar 2026 | -$293.78B | -122645.6% | — | 136.8% | |
| Peer median (excluding PYXS) | -$621.6M | -27.3% | — | 216.0% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 274.74M | 179.29M | 9.66M | 19.47M | 15.42M |
| Short-term Investments | 0 | 0 | 109.63M | 107.46M | 51.44M |
| Net Receivables | 0 | 598K | 21K | 0 | 700K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.56M | 5.41M | 4.27M | 4.75M | 4.55M |
| Total Current Assets | 278.67M | 186.61M | 124.6M | 132.44M | 72.11M |
| Property, Plant & Equipment (Net) | 1.24M | 24.77M | 24.81M | 22.14M | 19.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 24.31M | 2.6M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.35M | 24.77M | 49.12M | 24.74M | 19.42M |
| Total Assets | 280.02M | 211.38M | 173.73M | 157.18M | 91.52M |
| Account Payables | 11.95M | 7.1M | 3.9M | 4.86M | 10.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 7.66M | 0 | 0 |
| Other Current Liabilities | 3.23M | 5.33M | 5.58M | 4.63M | 3.75M |
| Total Current Liabilities | 18.71M | 31.63M | 25.76M | 17.68M | 21.13M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 2.16M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 18.92M | 22.26M | 18.75M | 16.98M |
| Total Liabilities | 18.71M | 50.56M | 48.02M | 36.43M | 38.11M |
| Common Stock | 32K | 34K | 45K | 60K | 63K |
| Retained Earnings | (91.72M) | (212.44M) | (286.23M) | (363.56M) | (443.18M) |
| Accumulated OCI | 0 | 0 | 63K | 170K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 261.31M | 160.82M | 125.7M | 120.75M | 53.41M |
| Total Debt | 165K | 18.92M | 21.33M | 20.2M | 18.67M |
| Net Debt | (274.57M) | (160.37M) | 11.67M | 727K | 3.25M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.